Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
161.13B
Market cap161.13B
Price-Earnings ratio
36.84
Price-Earnings ratio36.84
Dividend yield
6.18%
Dividend yield6.18%
Average volume
31.33M
Average volume31.33M
High today
$28.29
High today$28.29
Low today
$27.59
Low today$27.59
Open price
$27.62
Open price$27.62
Volume
23.20M
Volume23.20M
52 Week high
$29.21
52 Week high$29.21
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $28.27. The company's market cap stands at 161.13B, with a P/E ratio of 36.84 and a dividend yield of 6.18%.

During the trading session on 2026-10-09, Pfizer(PFE) shares reached a daily high of $28.29 and a low of $27.59. At a current price of $28.27, the stock is +2.5% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 23.2M, compared to an average daily volume of 31.33M.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

PFE News

Benzinga 8h
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh investor interest in vaccine makers, sending several biotechnolog...

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
24/7 Wall St. 9h
Pfizer's Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning

Investing Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning Pfizer's dividend yield has climbed well above what most blue-chip drugmaker...

Pfizer's Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
TipRanks 10h
Pfizer’s New RSV Vaccine Trial Targets Older Adults, Signaling Long-Term Growth Potential

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 3 study called “AN INTERVENTIONAL PHASE 3 STUDY TO E...

Analyst ratings

59%

of 29 ratings
Buy
31%
Hold
58.6%
Sell
10.3%

More PFE News

TipRanks 11h
Pfizer’s New Asthma Bet: Tilrekimig Phase 3 Trial Moves Forward

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. is running a Phase 3 study called “A Study to Learn About the Study Medicine...

24/7 Wall St. 11h
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

Investing Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80,...

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
TipRanks 13h
Pfizer price target raised to $30 from $28 at JPMorgan

JPMorgan raised the firm’s price target on Pfizer (PFE) to $30 from $28 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate sour...

24/7 Wall St. 15h
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

Investing Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVi...

Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
Simply Wall St 16h
Pfizer Stock Looks Expensive Following Its 18% One Year Gain

shares have climbed 18.0% over the past year, so the immediate question for anyone looking at the stock today is whether that move is matched by what the busine...

Pfizer Stock Looks Expensive Following Its 18% One Year Gain
TipRanks 1d
Pfizer’s VESPER-OSA 1 Trial Targets Sleep Apnea and Obesity With Monthly Shot

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer is advancing a late-stage trial that targets a common sleep breathing problem in p...

TipRanks 2d
Cboe data shows mixed options sentiment in Pfizer with shares down 1.38%

Cboe data shows mixed options sentiment in Pfizer (PFE), with shares down 38c near $27.61. Options volume roughly in line with average with 26k contracts traded...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.